Drug Transporters. Группа авторовЧитать онлайн книгу.

      14  7 MONOCARBOXYLIC ACID TRANSPORTERS 7.1 INTRODUCTION 7.2 SLC5 TRANSPORTER FAMILY 7.3 SLC16 TRANSPORTER FAMILY 7.4 CONCLUSIONS AND FUTURE PERSPECTIVES REFERENCES

      15  8 THE NUCLEOSIDE TRANSPORTERS CNTs AND ENTs 8.1 INTRODUCTION 8.2 MOLECULAR AND FUNCTIONAL CHARACTERISTICS OF CNTs (SLC28) 8.3 MOLECULAR AND FUNCTIONAL CHARACTERISTICS OF ENTs (SLC29) 8.4 METHODS AND MOUSE MODELS TO STUDY ENTs AND CNTs 8.5 REGULATION OF CNTs AND ENTs 8.6 PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL FUNCTIONS OF CNTs AND ENTs 8.7 THERAPEUTIC SIGNIFICANCE OF CNTs AND ENTs 8.8 CONCLUSIONS ACKNOWLEDGMENT REFERENCES

      16  9 BILE ACID TRANSPORTERS 9.1 INTRODUCTION 9.2 OVERVIEW OF TRANSPORTERS IN THE ENTEROHEPATIC CIRCULATION OF BILE ACIDS 9.3 HEPATOBILIARY BILE ACID TRANSPORTERS 9.4 INTESTINAL BILE ACID TRANSPORTERS 9.5 CONCLUSIONS AND FUTURE PERSPECTIVES REFERENCES

      17  10 THE P‐GLYCOPROTEIN MULTIDRUG TRANSPORTER 10.1 MULTIDRUG RESISTANCE AND P‐GLYCOPROTEIN 10.2 EXPRESSION PATTERN OF P‐GLYCOPROTEIN 10.3 SUBSTRATES AND INHIBITORS OF P‐GLYCOPROTEIN 10.4 STRUCTURE OF P‐GLYCOPROTEIN 10.5 EPITOPE MAPPING OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN P‐GLYCOPROTEIN (MRK‐16, 4E3, AND UIC2) 10.6 MOLECULAR MECHANISM OF POLYSPECIFICITY 10.7 DRUG TRANSPORT CYCLE OF P‐GLYCOPROTEIN 10.8 EFFORTS TO DISCOVER MODULATORS 10.9 ROLE OF P‐GLYCOPROTEIN IN THE PHYSIOLOGY AND BIOAVAILABILITY OF DRUGS 10.10 CONCLUSIONS AND FUTURE PERSPECTIVE ACKNOWLEDGMENTS REFERENCES

      18  11 MULTIDRUG RESISTANCE PROTEINS OF THE ABCC SUBFAMILY 11.1 INTRODUCTION 11.2 NOMENCLATURE AND MOLECULAR CHARACTERIZATION 11.3 EXPRESSION AND LOCALIZATION OF ABCC TRANSPORTERS IN NORMAL HUMAN TISSUES AND IN HUMAN CANCERS 11.4 FUNCTIONAL PROPERTIES/SUBSTRATE SPECIFICITY AND MULTIDRUG RESISTANCE PROFILES OF HUMAN ABCC/MRPS 11.5 CLINICAL CONSEQUENCES OF GENETIC VARIANTS IN ABCC GENES 11.6 CONCLUSION ACKNOWLEDGMENTS REFERENCES

      19  12 ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP) 12.1 DISCOVERY AND NOMENCLATURE 12.2 THE ABCG2 GENE AND EXPRESSION 12.3 PHYSICAL PROPERTIES 12.4 SUBSTRATES AND INHIBITORS OF BCRP 12.5 RECENT FINDINGS CONCERNING PHYSIOLOGICAL FUNCTIONS 12.6 PREDICTED PHYSIOLOGICAL FUNCTION FROM TISSUE DISTRIBUTION 12.7 ABCG2 EXPRESSION IN CANCER AND ITS ROLE IN DRUG RESISTANCE 12.8 GENETIC POLYMORPHISMS 12.9 CONCLUSION REFERENCES

      20  13 DRUG TRANSPORT IN THE LIVER 13.1 INTRODUCTION 13.2 HEPATIC PHYSIOLOGY: LIVER STRUCTURE AND FUNCTION 13.3 HEPATIC TRANSPORT PROTEINS 13.4 REGULATION OF HEPATIC TRANSPORT PROTEINS IN HUMANS 13.5 PHYSIOLOGICAL FACTORS THAT INFLUENCE HEPATIC DRUG TRANSPORT PROTEINS IN HUMANS 13.6 DISEASE‐RELATED ALTERATIONS IN HUMAN HEPATIC TRANSPORT PROTEINS 13.7 METHODS FOR STUDYING HEPATOBILIARY DRUG TRANSPORT 13.8 HEPATIC TRANSPORTER‐MEDIATED DRUG–DRUG INTERACTIONS (DDIS) 13.9 INTERPLAY BETWEEN DRUG METABOLISM AND TRANSPORT